DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury - PubMed (original) (raw)

doi: 10.1038/labinvest.2016.34. Epub 2016 Feb 15.

Jung Eun Kim 2, Mi Hwa Lee 2, Hye Kyoung Song 2, Jung Yeon Ghee 2, Young Sun Kang 2, Hye Sook Min 2, Hyun Wook Kim 1, Jin Joo Cha 2, Jee Young Han 3, Sang Youb Han 4, Dae Ryong Cha 2

Affiliations

Free article

DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury

Jee Eun Lee et al. Lab Invest. 2016 May.

Free article

Abstract

Although dipeptidyl peptidase IV (DPPIV) inhibitors are known to have renoprotective effects, the mechanism underlying these effects has remained elusive. Here we investigated the effects of DA-1229, a novel DPPIV inhibitor, in two animal models of renal injury including db/db mice and the adriamycin nephropathy rodent model of chronic renal disease characterized by podocyte injury. For both models, DA-1229 was administered at 300 mg/kg/day. DPPIV activity in the kidney was significantly higher in diabetic mice compared with their nondiabetic controls. Although DA-1229 did not affect glycemic control or insulin resistance, DA-1229 did improve lipid profiles, albuminuria and renal fibrosis. Moreover, DA-1229 treatment resulted in decreased urinary excretion of nephrin, decreased circulating and kidney DPPIV activity, and decreased macrophage infiltration in the kidney. In adriamycin-treated mice, DPPIV activity in the kidney and urinary nephrin loss were both increased, whereas glucagon-like peptide-1 concentrations were unchanged. Moreover, DA-1229 treatment significantly improved proteinuria, renal fibrosis and inflammation associated with decreased urinary nephrin loss, and kidney DPP4 activity. In cultured podocytes, DA-1229 restored the high glucose/angiotensin II-induced increase of DPPIV activity and preserved the nephrin levels in podocytes. These findings suggest that activation of DPPIV in the kidney has a role in the progression of renal disease, and that DA-1229 may exert its renoprotective effects by preventing podocyte injury.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Diabetes Investig. 2014 May 4;5(3):313-9 - PubMed
    1. Clin Ther. 2012 Sep;34(9):1986-98 - PubMed
    1. J Am Chem Soc. 2010 Mar 24;132(11):3819-30 - PubMed
    1. Life Sci. 2007 Jul 4;81(4):272-9 - PubMed
    1. Diabetes. 2013 Oct;62(10):3316-23 - PubMed

MeSH terms

Substances

LinkOut - more resources